Source: Annual Congress 2004 - Cardiovascular and metabolic consequences of OSA
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Sueyasu, T. Kitajima, A. Shimada, Y. Oshita, T. Koga, T. Rikimaru, H. Aizawa (Kurume, Japan). The role of inflammatory mediator in exhaled breath condensate of obstructive sleep apnea. Eur Respir J 2004; 24: Suppl. 48, 2096

Member's Comments

No comment yet.

Related content which might interest you: Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease Source: Eur Respir J 2005; 25: 269-274 Year: 2005 Factors influencing airway inflammation measured by exhaled NO levels in a population with obstructive sleep apnea syndrome (OSA) Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010 impact of continous positive airway pressure therapy on exhaled nitic oxide in obstructive sleep apnea syndrome Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation Year: 2019 Effect of nasal CPAP on exhaled nitric oxide in patients with obstructive sleep apnea Source: Eur Respir J 2007; 30: Suppl. 51, 332s Year: 2007 Exhaled breath condensate biomarkers in COPD Source: Eur Respir J 2008; 32: 472-486 Year: 2008 Myeloperoxidase in exhaled breath condensate reflects the status of lung parenchyma during the exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005 Exhaled breath markers in patients with obstructive sleep apnea (OSA): baseline assessment and the impact of treatment with nasal continuous positive airway pressure Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005 Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 467s Year: 2003 Overnight changes in exhaled carbon monoxide levels in obstructive sleep apnoea Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Metabolomic analysis of exhaled breath condensate in diagnostics of obstructive airway diseases Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Concentration of exhaled nitric oxide (FENO) in patients with obstructive sleep apnea Source: Eur Respir J 2004; 24: Suppl. 48, 118s Year: 2004 Cystenil-leukotrienes as markers of airway inflammation in exhaled breath condensate of asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 412s Year: 2002 Oxydative stress in obstructive sleep apnea (OSA). Exhaled breath condensate (EBC) measurements (H2O2) in the follow-up of patients under CPAP. First results Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007 Exhaled breath condensate for evaluation of inflammation in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 35s Year: 2006 Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008